A detailed history of Fortis Capital Management LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Fortis Capital Management LLC holds 12,092 shares of LYEL stock, worth $13,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,092
Previous 12,092 -0.0%
Holding current value
$13,301
Previous $17,000 5.88%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

BUY
$1.71 - $3.07 $20,677 - $37,122
12,092 New
12,092 $26,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Fortis Capital Management LLC Portfolio

Follow Fortis Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortis Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortis Capital Management LLC with notifications on news.